How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

11,121 results for

General Medical Books

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. The use of comic books, graphic novels, and fotonovelas as a health promotion tool

, and fotonovelas as health promotion tools (including HIV and STIs)? Key take-home messages Comics — including graphic novels, comic books, and fotonovelas — are one way to learn and teach about illness (1) as the reader can relate words and images to personal experience (2, 3). Generally, comics focused on health can fall into two different categories: memoirs about personal health or an experience of illness, and comics that consist of instructional content designed for education (4). The Undetectables (...) Intervention utilized a comic book series alongside interdisciplinary adherence support teams and financial incentives to promote adherence to HIV medication with favourable results (5). Fotonovela interventions demonstrated positive outcomes for several health conditions (6-8). There appears to be a limited amount of literature describing how to design or evaluate comics for health promotion purposes. The issue and why it’s important Visual narratives consist of literature that conveys a story through

2020 Ontario HIV Treatment Network

2. Guselkumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V

Guselkumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Guselkumab (Plaque-Psoriasis) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 27 February 2018). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A17-60 Guselkumab (...) (plaque psoriasis) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A17-60 Version 1.0 Guselkumab (plaque psoriasis) 27 February 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Guselkumab (plaque psoriasis) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded on: 23 November 2017

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

3. Dupilumab (atopic dermatitis) - Benefit assessment according to §35a Social Code Book (SGB) V

Dimension G-BA Gemeinsamer Bundesausschuss (Federal Joint Committee) IQWiG Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (Institute for Quality and Efficiency in Health Care) ITT intention to treat MedRA Medical Dictionary for Regulatory Activities Peak Pruritus NRS Peak Pruritus Numerical Rating Scale POEM Patient-Oriented Eczema Measure RCT randomized controlled trial SAE serious adverse event SCORAD Scoring Atopic Dermatitis SGB Sozialgesetzbuch (Social Code Book) SOC System Organ (...) Dupilumab (atopic dermatitis) - Benefit assessment according to §35a Social Code Book (SGB) V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Dupilumab (atopische Dermatitis) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 27 February 2018). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A17-63

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

4. Cladribine (multiple sclerosis) - Benefit assessment according to §35a Social Code Book (SGB) V

Cladribine (multiple sclerosis) - Benefit assessment according to §35a Social Code Book (SGB) V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Cladribin (multiple Sklerose) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 27 February 2018). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A17-62 (...) Cladribine (multiple sclerosis) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A17-62 Version 1.0 Cladribine (multiple sclerosis) 27 February 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Cladribine (multiple sclerosis) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded on: 30

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

5. Dapagliflozin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V (new scientific findings)

Dapagliflozin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V (new scientific findings) Extract 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Dapagliflozin (Diabetes mellitus Typ 2) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 28 March 2018). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG (...) Reports – Commission No. A17-65 Dapagliflozin (type 2 diabetes mellitus) – Benefit assessment according to §35a Social Code Book V 1 (new scientific findings) Extract of dossier assessment A17-65 Version 1.0 Dapagliflozin (type 2 diabetes mellitus) 28 March 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Dapagliflozin (type 2 diabetes mellitus) – Benefit assessment according to §35a Social

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

6. Alectinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V

Alectinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Alectinib (nicht kleinzelliges Lungenkarzinom) – Nutzenbewertung gemäß § 35a SGB V (neues Anwendungsgebiet) (Version 1.0; Status: 28 March 2018). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding (...) . IQWiG Reports – Commission No. A17-67 Alectinib (non-small cell lung cancer) – Benefit assessment according to §35a Social Code Book V 1 (new therapeutic indication) Extract of dossier assessment A17-67 Version 1.0 Alectinib (non-small cell lung cancer) 28 March 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Alectinib (non-small cell lung cancer) – Benefit assessment according to §35a

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

7. Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (HIV-infected children) - Benefit assessment according to §35a Social Code Book V

Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (HIV-infected children) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Elvitegravir/Cobicistat/Emtricitabin/Tenofovir- alafenamid (HIV-Infektion bei Kindern) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 12 April 2018). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German (...) original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A18-01 Elvitegravir/cobicistat/ emtricitabine/tenofovir alafenamide (HIV-infected children) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A18-01 Version 1.0 EVG/COBI/FTC/TAF (HIV-infected children) 12 April 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

8. Dapagliflozin/metformin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V (new scientific findings)

Dapagliflozin/metformin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V (new scientific findings) Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Dapagliflozin/Metformin (Diabetes mellitus Typ 2) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 28 March 2018). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative (...) and legally binding. IQWiG Reports A17-66 Dapagliflozin/metformin (type 2 diabetes mellitus) – Benefit assessment according to §35a Social Code Book V 1 (new scientific findings) Extract of dossier assessment A17-66 Version 1.0 Dapagliflozin/metformin (type 2 diabetes mellitus) 28 March 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Dapagliflozin/metformin (type 2 diabetes mellitus) – Benefit

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

9. Sonidegib (basal cell carcinoma) – Benefit assessment according to §35a Social Code Book V

Sonidegib (basal cell carcinoma) – Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Sonidegib (Basalzellkarzinom) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 9 May 2018). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A18-10 Sonidegib (...) (basal cell carcinoma) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A18-10 Version 1.0 Sonidegib (basal cell carcinoma) 9 May 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Sonidegib (basal cell carcinoma) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded on: 14 February

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

10. Lumacaftor/ivacaftor (cystic fibrosis) - Benefit assessment according to §35a Social Code Book V

Lumacaftor/ivacaftor (cystic fibrosis) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Lumacaftor/Ivacaftor (zystische Fibrose) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 27 April 2018). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission (...) No. A18-08 Lumacaftor/ivacaftor (cystic fibrosis) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A18-08 Version 1.0 Lumacaftor/ivacaftor (cystic fibrosis) 27 April 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Lumacaftor/ivacaftor (cystic fibrosis) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

11. Abiraterone acetate (prostate cancer) - Benefit assessment according to §35a Social Code Book V

Abiraterone acetate (prostate cancer) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Abirateronacetat (Prostatakarzinom) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 13 March 2018). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A17-64 (...) Abiraterone acetate (prostate cancer) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A17-64 Version 1.0 Abiraterone acetate (prostate cancer) 13 March 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Abiraterone acetate (prostate cancer) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

12. Benralizumab (asthma) - Benefit assessment according to §35a Social Code Book V

Benralizumab (asthma) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Benralizumab (Asthma) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 9 May 2018). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A18-11 Benralizumab (asthma) – Benefit (...) assessment according to §35a Social Code Book V 1 Extract of dossier assessment A18-11 Version1.0 Benralizumab (asthma) 9 May 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Benralizumab (asthma) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded on: 15 February 2018 Internal Commission No.: A18-11 Address of publisher

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

13. Ipilimumab (melanoma) - Benefit assessment according to §35a Social Code Book V

Ipilimumab (melanoma) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Ipilimumab (Melanom) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 9 May 2018). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A18-12 Ipilimumab (melanoma) – Benefit (...) assessment according to §35a Social Code Book V 1 Extract of dossier assessment A18-12 Version 1.0 Ipilimumab (melanoma) 9 May 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Ipilimumab (melanoma) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded on: 15 February 2018 Internal Commission No.: A18-12 Address of publisher

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

14. Ixekizumab (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V

Ixekizumab (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Ixekizumab (Psoriasis Arthritis) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 30 May 2018). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A18-14 Ixekizumab (...) (psoriatic arthritis) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A18-14 Version 1.0 Ixekizumab (psoriatic arthritis) 30 May 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Ixekizumab (psoriatic arthritis) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded on: 20 February 2018

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

15. Melatonin (sleep disorders) - Benefit assessment according to §35a Social Code Book V

Melatonin (sleep disorders) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Melatonin (Schlafstörungen bei Kindern und Jugendlichen mit Autismus-Spektrum-Störung und/oder Smith-Magenis-Syndrom) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 11 April 2019). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely (...) authoritative and legally binding. IQWiG Reports – Commission No. A19-04 Melatonin (Insomnia in children and adolescents with autism spectrum disorder and/or Smith-Magenis syndrome) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A19-04 Version 1.0 Melatonin (Insomnia in children and adolescents with ASD and/or SMS) 11 April 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

16. Apalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V

Apalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Apalutamide (Prostatakarzinom) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 29 April 2019). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A19-09 Apalutamide (...) (prostate cancer) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A19-09 Version 1.0 Apalutamide (prostate cancer)) 24 April 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Apalutamide (prostate cancer) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded on: 24 January 2019 Internal

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

17. Ipilimumab (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V

Ipilimumab (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Ipilimumab (Nierenzellkarzinom) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 13 May 2019). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A19-12 Ipilimumab (...) (renal cell carcinoma) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A19-12 Version 1.0 Ipilimumab (renal cell carcinoma) 13 May 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Ipilimumab (renal cell carcinoma) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded on: 4 February

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

18. Lenvatinib (thyroid carcinoma) - Benefit assessment according to §35a Social Code Book V

assessment). EQ-5D: European Quality of Life-5 Dimensions; FACT-G: Functional Assessment of Cancer Therapy- General; ND: no data; PFS: progression-free survival; RCT: randomized controlled trial; VAS: visual analogue scale; vs.: versus The observation periods for the outcomes on side effects were systematically shortened because they were only recorded for the time period of treatment with the study medication (plus 30 days). To be able to draw a reliable conclusion on the total study period or the time (...) Lenvatinib (thyroid carcinoma) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Lenvatinib (Schilddrüsenkarzinom) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 13 May 2019). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A19-19 Lenvatinib

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

19. Rucaparib (ovarian, fallopian tube or peritoneal cancer; maintenance treatment) - Benefit assessment according to §35a Social Code Book V

Rucaparib (ovarian, fallopian tube or peritoneal cancer; maintenance treatment) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Rucaparib (Ovarialkarzinom; Erhaltungstherapie) – Nutzenbewertung gemäß § 35a SGB V (Version 1.1; Status: 7 August 2019). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative (...) and legally binding. IQWiG Reports – Commission No. A19-23 Rucaparib (ovarian cancer; maintenance treatment) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A19-23 Version 1.1 Rucaparib (ovarian cancer; maintenance treatment) 7 August 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Rucaparib (ovarian cancer; maintenance treatment) – Benefit assessment

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

20. Galcanezumab (migraine) - Benefit assessment according to §35a Social Code Book V

Galcanezumab (migraine) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.7 of the dossier assessment Galcanezumab (Migräne) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 27 June 2019). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A19-28 Galcanezumab (migraine (...) ) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A19-28 Version 1.0 Galcanezumab (migraine) 27 June 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Galcanezumab (migraine) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded on: 29 March 2019 Internal Commission No.: A19-28 Address

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>